종양학 분야 동반진단 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Companion Diagnostic Tests in Oncology Market size is expected to reach USD 18.93 Billion in 2034 from USD 8.02 Billion (2025) growing at a CAGR of 10.01% during 2026-2034.

The global companion diagnostic tests in oncology market is expanding rapidly as personalized medicine becomes more important in cancer treatment. Companion diagnostics are tests that help determine whether a patient is likely to benefit from a specific cancer therapy. These tests analyze genetic mutations, biomarkers, or other molecular characteristics of tumors to guide treatment decisions.

The increasing prevalence of cancer worldwide and the growing adoption of targeted therapies are major drivers of market growth. Pharmaceutical companies and diagnostic manufacturers are collaborating to develop companion diagnostic tests alongside new cancer drugs. Advances in molecular diagnostics and genomic sequencing technologies are also improving the accuracy and reliability of these tests.

Looking ahead, the market is expected to grow significantly as precision oncology continues to evolve. Increasing research in cancer genomics and biomarker discovery will lead to the development of new diagnostic tools. As healthcare providers focus on delivering personalized cancer treatments, companion diagnostic testing will play an essential role in improving treatment outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Detection Technique

• Protein Detection
• DNA Detection
• Others

By Biomarker

• EGFR
• KRAS
• HER2
• BRAF V600E
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Liver Cancer
• Melanoma
• Others

By End-user

• Hospitals
• Specialty Clinics
• Diagnostic Labs
• Others

COMPANIES PROFILED

• Abbott Laboratories, F HoffmannLa Roche Ltd, Genomic Health Inc, Qiagen NV, Agilent Technologies Inc, Agendia NV, bioMrieux SA, Illumina Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, BioGenex Laboratories Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY DETECTION TECHNIQUE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Detection Technique
• 4.2. Protein Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. DNA Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY BIOMARKER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Biomarker
• 5.2. EGFR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. KRAS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HER2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. BRAF V600E Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Cancer Type
• 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Diagnostic Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Detection Technique
  • 8.2.2 By Biomarker
  • 8.2.3 By Cancer Type
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Detection Technique
  • 8.3.2 By Biomarker
  • 8.3.3 By Cancer Type
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Detection Technique
  • 8.4.2 By Biomarker
  • 8.4.3 By Cancer Type
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Detection Technique
  • 8.5.2 By Biomarker
  • 8.5.3 By Cancer Type
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Detection Technique
  • 8.6.2 By Biomarker
  • 8.6.3 By Cancer Type
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 F. Hoffmann-La Roche Ltd
  • 10.2.3 Genomic Health Inc
  • 10.2.4 Qiagen N.V
  • 10.2.5 Agilent Technologies Inc
  • 10.2.6 Agendia N.V
  • 10.2.7 BioMAfA(C)Rieux SA
  • 10.2.8 Illumina Inc
  • 10.2.9 Siemens Healthineers AG
  • 10.2.10 Thermo Fisher Scientific Inc
  • 10.2.11 BioGenex Laboratories Inc